Relapsed And Or Refractory Multiple Myeloma clinical trials

Explore recruiting relapsed and or refractory multiple myeloma clinical trials.

Recruiting relapsed and or refractory multiple myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed And Or Refractory Multiple Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma

Spain, France, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM

Germany, Italy, Sweden, Romania, Ireland, Czechia +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2a, Multicenter, Open-Label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination with Mezigdomide in Participants with Relapsed and/or Refractory Multiple Myeloma

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma.

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination with Elranatamab in Participants with Relapsed and/or Refractory Multiple Myeloma

Norway, Greece, Germany, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM)

Greece, Czechia, Portugal

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapsed And Or Refractory Multiple Myeloma trials by city

Relapsed And Or Refractory Multiple Myeloma in Toronto Relapsed And Or Refractory Multiple Myeloma in Vancouver Relapsed And Or Refractory Multiple Myeloma in Montreal Relapsed And Or Refractory Multiple Myeloma in Calgary Relapsed And Or Refractory Multiple Myeloma in Edmonton Relapsed And Or Refractory Multiple Myeloma in Ottawa Relapsed And Or Refractory Multiple Myeloma in Winnipeg Relapsed And Or Refractory Multiple Myeloma in Quebec City Relapsed And Or Refractory Multiple Myeloma in Hamilton Relapsed And Or Refractory Multiple Myeloma in Kitchener Relapsed And Or Refractory Multiple Myeloma in London Relapsed And Or Refractory Multiple Myeloma in Halifax Relapsed And Or Refractory Multiple Myeloma in New York Relapsed And Or Refractory Multiple Myeloma in Los Angeles Relapsed And Or Refractory Multiple Myeloma in Chicago Relapsed And Or Refractory Multiple Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease